This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jakobsen, A. Articles by Lindeberg, J. Search for Related Content PubMed PubMed Citation Articles by Jakobsen, A. Articles by Lindeberg, J.

Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphism in Normal Tissue As Predictors of Fluorouracil Sensitivity

From the Danish Colorectal Cancer Group South, Vejle Hospital, Vejle, Denmark

Address reprint requests to Anders Jakobsen, MD, Department of Oncology, Vejle Hospital, 7100 Vejle, Denmark; e-mail: aja{at}vs.vejleamt.dk

PURPOSE: To analyze thymidylate synthase (TS) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphism with respect to fluorouracil (FU) sensitivity.

PATIENTS AND METHODS: The study included a retrospective analysis of 88 patients with metastatic colorectal cancer and a prospective trial with 51 patients also with measurable metastases. All patients were treated with FU and leucovorin. The analysis of gene polymorphism was performed on normal intestinal tissue and lymphocytes.

RESULTS: The response rate was significantly higher in patients with TS 3R/3R or MTHFR 677 TT gene polymorphism compared with the other groups. The difference of response rate translated to a difference in time to progression. Similar results were observed in the retrospective analysis and the prospective confirmatory trial.

CONCLUSION: The analysis of gene polymorphism allows delineation of a group of patients (30%) with a response rate to a single drug of approximately 50%. This information should be used in the design of tailored treatment.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				M. Schwab, U. M. Zanger, C. Marx, E. Schaeffeler, K. Klein, J. Dippon, R. Kerb, J. Blievernicht, J. Fischer, U. Hofmann, et al. Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group J. Clin. Oncol., May 1, 2008; 26(13): 2131 - 2138. [Abstract] [Full Text] [PDF]

				R. Sharma, J. M. Hoskins, L. P. Rivory, M. Zucknick, R. London, C. Liddle, and S. J. Clarke Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients Clin. Cancer Res., February 1, 2008; 14(3): 817 - 825. [Abstract] [Full Text] [PDF]

				A. Ruzzo, F. Graziano, F. Loupakis, E. Rulli, E. Canestrari, D. Santini, V. Catalano, R. Ficarelli, P. Maltese, R. Bisonni, et al. Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy J. Clin. Oncol., April 1, 2007; 25(10): 1247 - 1254. [Abstract] [Full Text] [PDF]

				G. Y. Locker, S. Hamilton, J. Harris, J. M. Jessup, N. Kemeny, J. S. Macdonald, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer J. Clin. Oncol., November 20, 2006; 24(33): 5313 - 5327. [Abstract] [Full Text] [PDF]

				W. Ichikawa, T. Takahashi, K. Suto, Y. Sasaki, and R. Hirayama Orotate Phosphoribosyltransferase Gene Polymorphism Predicts Toxicity in Patients Treated with Bolus 5-Fluorouracil Regimen. Clin. Cancer Res., July 1, 2006; 12(13): 3928 - 3934. [Abstract] [Full Text] [PDF]

				A. Ruzzo, F. Graziano, K. Kawakami, G. Watanabe, D. Santini, V. Catalano, R. Bisonni, E. Canestrari, R. Ficarelli, E. T. Menichetti, et al. Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy J. Clin. Oncol., April 20, 2006; 24(12): 1883 - 1891. [Abstract] [Full Text] [PDF]

				E. Dotor, M. Cuatrecases, M. Martinez-Iniesta, M. Navarro, F. Vilardell, E. Guino, L. Pareja, A. Figueras, D. G. Mollevi, T. Serrano, et al. Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant Treatment J. Clin. Oncol., April 1, 2006; 24(10): 1603 - 1611. [Abstract] [Full Text] [PDF]

				J. M. Engles, S. A. Quarless, E. Mambo, T. Ishimori, S. Y. Cho, and R. L. Wahl Stunning and Its Effect on 3H-FDG Uptake and Key Gene Expression in Breast Cancer Cells Undergoing Chemotherapy J. Nucl. Med., April 1, 2006; 47(4): 603 - 608. [Abstract] [Full Text] [PDF]

				F. Graziano and K. Kawakami Studying the Predictive/Prognostic Role of Thymidylate Synthase Genotypes in Patients With Colorectal Cancer: Is One Polymorphism Enough? J. Clin. Oncol., October 1, 2005; 23(28): 7230 - 7231. [Full Text] [PDF]